Moderna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due...
GENERAL COMMENTS Today, the Federal Reserve maintained its interest rates unchanged, highlighting the ongoing challenges in curbing inflation. Initially, this announcement propelled the markets upwards, but a sharp downturn occurred in the final hour, leading to a decline as the day concluded. The erratic market behavior demonstrated today makes it increasingly...
Biotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend with XBI pivoting to bullish back in early November. I add long positions when I...
If you haven`t sold MRNA at all time high: Then analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week, I would consider purchasing the 115usd strike price Calls with an expiration date of 2024-7-19, for a premium of approximately $8.00. If these options prove to be profitable prior to the earnings release, I...
In a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology...
🔉Sound on!🔉 Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
NASDAQ:MRNA Bearish to Bullish Reversal A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a...
Moderna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be...
Today NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal...
MRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area...
NVAX on a 120 minute chart demonstrates a trend down in the past month after a period of consolidation producing the POC line on the volume profile. The MACD shows some bullish divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative volume void. NVAX fell quickly through that void. It can just as easily rise through it....
NVAX on the 15 minute chart has been compressing price action volatility into a symmetrical triangle. It in now in a breakout of the triangle and in the process when from undervalued on Monday to the upper trendline and then down to the support trendline and then up again. It passed through the volume profile and its high volume area. In short, it has bullish...
The mRNA stock has exhibited a bullish flag breakout, following the identification of a falling wedge pattern. We anticipate a potential retracement towards the prominent key level near $130, which was established at the top.
Moderna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause. Unveiling the Numbers: Moderna's (...
Moderna has recently garnered attention for its significant rebound after a challenging 2023. The biotech company, primarily known for its groundbreaking COVID-19 vaccine, is poised for a transformative journey ahead, with a strategic pipeline that extends far beyond pandemic management. This Idea delves into the recent surge in Moderna's stock, the pivotal role...
Moderna has had an astronomical rise due to the vaccine. The technical setup looks excellent to the short side. TD9's on the daily, 2 day, 3 day, big divergences on many timeframes. That said - there is headline risk with this - if they get FDA approval it would likely squeeze.
Moderna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said that after about three years, the combination...
Its way overbought and numbers looks good. Technically sitting at a good support and can jump anytime. Within 3-5 years, it can give you back 70% gains.